Saturday 17 October 2026
Export ATR’s income statement to Excel — free account
AptarGroup, Inc.
ATR Healthcare Medical Instruments & Supplies
AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024. In the quarter to June 2026, revenue grew 6.26%, EPS fell 18.3%, free cash flow fell 23.1% and total debt rose 66.4%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten.
124.51
0.25
+0.20%
Follow ATR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.36 | 21.32 | 20.43 | 21.05 |
+8 more quarters Free account |
P/S ratio |
2.03 | 2.08 | 2.12 | 2.40 | |
P/FCF ratio |
25.33 | 24.56 | 26.90 | 28.45 | |
P/Operating CF |
76.99 | 68.00 | 43.65 | 49.45 | |
P/B ratio |
3.01 | 3.05 | 2.99 | 3.15 | |
Price to Tangible BV |
5.93 | 6.07 | 5.93 | 6.01 | |
EV/Sales |
2.32 | 2.38 | 2.41 | 2.65 | |
EV/EBITDA |
11.65 | 11.62 | 11.53 | 12.25 | |
EV/Operating CF |
15.66 | 15.20 | 15.95 | 17.21 | |
EV/FCF |
29.05 | 28.02 | 30.50 | 31.48 | |
Quick Ratio |
0.96 | 1.00 | 1.04 | 0.71 | |
Current Ratio |
1.61 | 1.66 | 1.62 | 1.19 | |
Net Debt/EBITDA |
5.67 | 6.20 | 5.87 | 4.41 | |
Debt/Assets |
26.64% | 26.79% | 28.23% | 23.54% | |
Debt/Equity |
0.52 | 0.52 | 0.55 | 0.43 | |
Asset Turnover |
0.79 | 0.80 | 0.78 | 0.75 | |
Operating CF/Net income |
1.18 | 1.63 | 2.47 | 1.39 | |
Capex/Depreciation |
(0.71) | (0.85) | (1.12) | (0.82) | |
Interest Coverage |
7.92 | 6.34 | 6.25 | 10.12 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.37% | 17.05% | 15.72% | 15.48% | |
Intangible Assets out of Total Assets |
0.25 | 0.26 | 0.25 | 0.26 | |
Share Based Compensation of Revenue |
0.71% | 1.71% | 0.74% | 1.00% | |
Graham Net Nets |
(0.08) | (0.08) | (0.08) | (0.06) | |
Graham Number |
72.39 | 74.14 | 74.08 | 77.85 | |
Earnings Yield |
4.47% | 4.69% | 4.90% | 4.75% | |
Free Cash Flow Yield |
3.95% | 4.07% | 3.72% | 3.51% | |
Revenue per Share |
16.13 | 15.35 | 14.64 | 14.63 | |
Operating CF per Share |
1.63 | 1.85 | 2.79 | 2.70 | |
Capex per Share |
(0.89) | (1.01) | (1.31) | (0.94) | |
Free Cash Flow per Share |
0.74 | 0.84 | 1.48 | 1.77 | |
Cash per Share |
3.10 | 3.58 | 6.23 | 4.03 | |
Shareholders Equity per Share |
41.59 | 41.34 | 40.86 | 42.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
41.59 | 41.34 | 40.86 | 42.42 | |
Free Cash Flow |
46.93 | 54.03 | 97.60 | 116.02 | |
Working Capital |
698.27 | 705.24 | 727.12 | 284.41 | |
Capital Expenditures |
(56.56) | (64.66) | (86.09) | (61.58) | |
Net Current Asset Value |
(651.67) | (681.95) | (673.18) | (529.71) | |
EV/EBIT |
19.14 | 18.60 | 18.14 | 18.88 | |
Capex to Sales |
0.06 | 0.07 | 0.09 | 0.06 | |
Price to Operating Income |
16.69 | 16.30 | 16.00 | 17.06 | |
| Other line items | |||||
Average Receivables |
848.94 | 787.99 | 730.94 | 749.00 | |
Average Payables |
852.33 | 801.75 | 776.45 | 809.08 | |
Average Inventory |
553.78 | 517.50 | 499.83 | 517.92 | |
Average Assets |
4,999.30 | 4,812.44 | 4,842.50 | 4,863.03 | |
Average Common Equity |
2,682.27 | 2,599.55 | 2,585.95 | 2,670.59 |
Columns are period end dates